Cardiovascular Devices Market

Cardiovascular Devices Market Size, Share, Growth Analysis, By Product (Diagnostic & Monitoring Devices, Surgical Devices), By Application (Coronary Artery Disease, Cardiac Arrhythmia), By End User (Hospitals, Specialty Clinics), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35E2016 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 91 | Figures: 76

Cardiovascular Devices Market News

  • October 2022: Medtronic plc received United States FDA approval to expand cardiac lead labeling by stimulating the heart’s natural electrical current, allowing patients to receive the treatment. 
  • March 2024: Stryker introduced the LIFEPAK CR2 AED and evacuation chair for cardiac monitoring. The LIFEPAK CR2 helps rescuers quickly deliver CPR and shock in the event of sudden cardiac arrest, with the quick deployment of QUIK-STEP electrodes and a Shock Advisory System for ECG monitoring.  
  • October 2022: Biosense Webster, Inc., a division of Johnson & Johnson MedTech, launched the HELIOSTAR balloon ablation catheter in Europe. The HELIOSTAR balloon ablation catheter is indicated for use in catheter-based cardiac electrophysiological mapping (and stimulation and recording) of the atria, and when used with a compatible multichannel RF generator, for use in the heart.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cardiovascular Devices Market size was valued at USD 44.9 billion in 2022 and is poised to grow from USD 49.1 billion in 2023 to USD 94.9 billion by 2031, growing at a CAGR of 8.5% during the forecast period (2024-2031). 

The cardiovascular devices market is competitive, dominated by established medical technology companies and driven by continuous innovation, a collaborative approach and a focus on expanding global reach. These agencies have constructed a vast market percentage via complicated cardiovascular solutions, from implantable devices together with pacemakers and stents to advanced imaging systems. Key players use partnerships and acquisitions to gain competitive benefit and drive growth. 'Abbott Laboratories ', 'Boston Scientific Corporation ', 'Medtronic, Inc. ', 'Johnson & Johnson ', 'Terumo Corporation ', 'Edwards Lifesciences Corporation ', 'Biotronik SE & Co. KG ', 'LivaNova PLC ', 'Getinge AB ', 'Baxter International Inc.  (Hill-Rom Holdings, Inc.) ', 'Koninklijke Philips N.V. ', 'Siemens Healthineers AG ', 'GE Healthcare ', 'Toshiba Corporation ', 'Fujifilm Holdings Corporation ', 'Hitachi, Ltd. ', 'Nihon Kohden Corporation ', 'Collateral Medical Pvt. Ltd. ', 'Schiller AG ', 'B. Braun Melsungen AG '

Worldwide, cardiovascular diseases (CVDs) are the leading cause of death, driving the demand for advanced medical devices. Sedentary lifestyles, poor dietary intake, and an aging population increase the risk of cardiovascular conditions such as congestive heart failure, heart failure and hypertension. Consequently, life-saving devices such as pacemakers, defibrillators and stents are increasingly needed in developed and developing areas as health systems prioritize preventive care with early detection of disease. Hospitals and clinics following the pace of using cutting-edge technology to improve patient outcomes, government programs and nonprofits are launching programs to raise awareness of high-risk populations have been monitored. 

Expanding Home Health Solutions: Trends in home healthcare and self-management are changing the cardiovascular devices market. Wearable ECG devices, blood pressure monitors, and remote patient monitoring methods provide real-time data, allowing individuals to manage chronic heart failure without repeated hospital visits. This trend is not to make patients not only easier, reducing the healthcare costs but supporting the transition to preventative healthcare.  

As per cardiovascular devices market outlook, North America dominated the market and accounted for the largest revenue share at 47.7% in 2024, driven by rising atrial fibrillation (AFib) & cardiovascular disease (CVD), supportive government policies and the technological advancements. This atrial fibrillation (AF) is very common, which is considered a risk factor for it has a lifetime incidence of approximately 1 in 3 to 5 people over the age of 45. AFib leads to significant hospitalization and death establish the urgent need for advanced cardiovascular emphasis devices each year. The market has grown with the increase in the prevalence of AFIB among older people in Canada. Important government initiatives supporting health promotion such as national research networks and provincial investments.  

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Structural Heart Devices Market
Buy Now GET FREE SAMPLE
Interventional Cardiology Devices Market
Buy Now GET FREE SAMPLE
Heart Pump Device Market
Buy Now GET FREE SAMPLE
Peripheral Vascular Devices Market
Buy Now GET FREE SAMPLE
Cardiac Assist Devices Market
Buy Now GET FREE SAMPLE
Neurovascular Devices Market
Buy Now GET FREE SAMPLE
Cardiac Rhythm Management Devices Market
Buy Now GET FREE SAMPLE
Medical Devices Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Cardiovascular Devices Market

Report ID: SQMIG35E2016

$5,300
BUY NOW GET FREE SAMPLE